Search

Your search keyword '"Brown J.R."' showing total 45 results

Search Constraints

Start Over You searched for: Author "Brown J.R." Remove constraint Author: "Brown J.R." Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
45 results on '"Brown J.R."'

Search Results

2. The relative efficacy of multiple syringe tip disinfection techniques against virulent staphylococcus contamination.

3. Characterizing the molecular epidemiology of anaesthesia work area transmission of Staphylococcus aureus sequence type 5.

4. SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

5. Transmission of Staphylococcus aureus in the anaesthesia work area has greater risk of association with development of surgical site infection when resistant to the prophylactic antibiotic administered for surgery.

7. Recent results in fragmentation isomer spectroscopy with rising

9. A direct measurement of the 17O(α,γ)21Ne reaction in inverse kinematics and its impact on heavy element production

11. Influenza virus survival in aerosols and estimates of viable virus loss resulting from aerosolization and air-sampling.

12. Optimisation of Bio-Oil Extraction Process from Beauty Leaf (Calophyllum Inophyllum) Oil Seed as a Second Generation Biodiesel Source.

14. Influence of monocaprin on the permeability of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs

16. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial.

17. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial.

18. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial.

19. Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial.

22. 1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC).

23. 1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis.

24. 1988P Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study.

25. 1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C.

Catalog

Books, media, physical & digital resources